Epidemiological features and antiviral response of genotype 6 chronic hepatitis C

Jinni HUANG; Jianning JIANG; Dandan LIANG; Shiyu LONG; Guozhen DONG; Man SU; Jijiao LI; Chunling TENG; Ping ZHANG; Minghua SU

doi:10.3969/j.issn.1001-5256.2022.04.011

Volume 38 Issue 4

Apr. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(4): 793-797

PDF( 2318 KB)

Epidemiological features and antiviral response of genotype 6 chronic hepatitis C

DOI: 10.3969/j.issn.1001-5256.2022.04.011

Department of Infection Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

Research funding:

Guangxi Medical and Health Appropriate Technology Development and Application Project (S2019108);

Qingxiu District Scientific Research and Technology Development Project of Nanning City (2013ZH02);

Guangxi Zhuang Autonomous Region Education Department University Scientific Research Project (YB2014064)

More Information

Corresponding author: SU Minghua, smh9292@163.com(ORCID: 0000-0001-7831-6580)
Received Date: 2021-08-11
Accepted Date: 2021-09-14
Published Date: 2022-04-20

Abstract

Abstract

Objective To investigate the epidemiological features and antiviral response of patients with genotype 6 chronic hepatitis C (CHC) in Guangxi, China. Methods A total of 97 patients with genotype 6 CHC who were admitted to The First Affiliated Hospital of Guangxi Medical University from December 2012 to December 2020 were enrolled, among whom 62 patients were given antiviral therapy. The 62 patients receiving antiviral therapy were divided into interferon group with 22 patients and direct-acting antiviral agent (DAA) group with 40 patients. Related data were collected, including general demographic data, HCV RNA, liver function, routine blood test results, and renal function. The chi-square test was used for comparison of categorical data between groups. Results Among the 97 patients, there were 69 male patients (71.1%) and 28 female patients (28.9%), with a mean age of 41.97±10.12 years, and the patients aged 30-40 years accounted for 47.4% (46/97). Of all 97 patients, 95 (97.9%) had genotype 6a, 1 had genotype 6e, and 1 had genotype 6xa. Among the 65 patients with a definite route of infection, 41 (63.1%) had intravenous drug use, 14 had medical-related operations, 9 had blood transfusion, and 4 had sexual contact as the route of infection. For the interferon group, the rapid virologic response (RVR) rate at week 4 was 81.8% (18/22), the rate of undetectable virus at the time of drug withdrawal (Epoint) was 86.4% (19/22), the rate of sustained virologic response at 12 weeks after drug withdrawal (SVR12) was 81.8%, and the rate of sustained virological response at 24 weeks after drug withdrawal (SVR24) was 81.8%; 1 patient in this group experienced recurrence. All 40 patients in the DAA group were previously untreated patients (33 patients without liver cirrhosis and 7 patients with compensated liver cirrhosis), with an overall RVR rate of 87.5%(35/40), an Epoint rate of 100%, and an SVR12 rate of 100%, and there was no treatment failure or recurrence. Although different DAA regimens had different RVR rates, they all had a SVR12 rate of 100%. The patients with compensated liver cirrhosis and other diseases had a SVR12 rate of 100%. Conclusion Intravenous drug addiction is the main route of infection for patients with genotype 6 CHC in Guangxi, and CHC is more common in men, with genotype 6a as the main subtype. DAA treatment has a higher virologic response rate than interferon treatment, with an SVR12 rate of 100%. There is no significant difference in SVR12 rate between the patients with compensated liver cirrhosis and those without liver cirrhosis.
- Hepatitis C,
- Epidemiology,
- Therapeutics

FullText(HTML)

References(24)

References

[1]	LAVANCHY D. The global burden of hepatitis C[J]. Liver Int, 2009, 29(Suppl 1): 74-81. DOI: 10.1111/j.1478-3231.2008.01934.x.
[2]	MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology, 2013, 57(4): 1333-1342. DOI: 10.1002/hep.26141.
[3]	CHEN YS, LI L, CUI FQ, et al. A sero-epidemiological study on hepatitis C in China[J]. Chin J Epidemiol, 2011, 3(9): 888-891. DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009. 陈园生, 李黎, 崔富强, 等. 中国丙型肝炎血清流行病学研究[J]. 中华流行病学杂志, 2011, 3(9): 888-891. DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009.
[4]	FATTOVICH G, STROFFOLINI T, ZAGNI I, et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors[J]. Gastroenterology, 2004, 127(5 Suppl 1): S35-S50. DOI: 10.1053/j.gastro.2004.09.014.
[5]	The field of anti-HCV therapy is progressing rapidly, and hepatitis C can be cured[J]. Chin Community Doct, 2018, 34(28): 172. 抗HCV治疗领域进展迅速, 丙肝已经可以治愈[J]. 中国社区医师, 2018, 34(28): 172.
[6]	LEE MH, HSIAO TI, SUBRAMANIAM SR, et al. HCV genotype 6 increased the risk for hepatocellular carcinoma among asian patients with liver cirrhosis[J]. Am J Gastroenterol, 2017, 112(7): 1111-1119. DOI: 10.1038/ajg.2017.123.
[7]	FEENEY ER, CHUNG RT. Antiviral treatment of hepatitis C[J]. BMJ, 2014, 348: g3308. DOI: 10.1136/bmj.g3308.
[8]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
[9]	LI C, PHAM VH, ABE K, et al. Nine additional complete genome sequences of HCV genotype 6 from Vietnam including new subtypes 6xb and 6xc[J]. Virology, 2014, 468-470: 172-177. DOI: 10.1016/j.virol.2014.08.006.
[10]	THONG VD, AKKARATHAMRONGSIN S, POOVORAWAN K, et al. Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication[J]. World J Gastroenterol, 2014, 20(11): 2927-2940. DOI: 10.3748/wjg.v20.i11.2927.
[11]	TSUKIYAMA-KOHARA K, KOHARA M. Hepatitis C virus: Viral quasispecies and genotypes[J]. Int J Mol Sci, 2017, 19(1): 23. DOI: 10.3390/ijms19010023.
[12]	LI C, BARNES E, NEWTON PN, et al. An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes[J]. Virology, 2015, 476: 355-363. DOI: 10.1016/j.virol.2014.12.025.
[13]	METTIKANONT P, BUNCHORNTAVAKUL C, REDDY KR. Systematic review: Epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection[J]. Aliment Pharmacol Ther, 2019, 49(5): 492-505. DOI: 10.1111/apt.15100.
[14]	CHEN Y, YU C, YIN X, et al. Hepatitis C virus genotypes and subtypes circulating in Mainland China[J]. Emerg Microbes Infect, 2017, 6(11): e95. DOI: 10.1038/emi.2017.77.
[15]	MOHD SUAN MA, SAID SM, LIM PY, et al. Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study[J]. PLoS One, 2019, 14(10): e0224459. DOI: 10.1371/journal.pone.0224459.
[16]	MAO Q. Changes in the distribution pattern of HCV genotypes in China and the RGT strategy of HCV-6[C]//The 4th National Academic Conference on Progress in Basic and Clinical Research on Chronic and Severe Viral Hepatitis. 2014: 111-112. 毛青. 中国HCV基因型分布模式变迁及HCV-6型的RGT策略[C]//第四届全国病毒性肝炎慢性化、重症化基础与临床研究进展学术会议论文汇编. 2014: 111-112.
[17]	TANG W, SU MH, JIANG JN, et al. Epidemiological characteristics and genotype distribution of hepatitis C virus in Guangxi[J]. World Chin J Dig, 2014, 22(9): 1300-1306. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201409022.htm 唐维, 苏明华, 江建宁, 等. 广西地区丙型肝炎病毒的基因型分布与流行病学特征[J]. 世界华人消化杂志, 2014, 22(9): 1300-1306. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201409022.htm
[18]	WEI Z, SU MH, JIANG JN, et al. Epidemiological characteristics and therapeutic strategies of hepatitis C virus genotype 6 in Guangxi area[J]. Chin J Infect Dis, 2015, 33(7): 409-414. DOI: 10.3760/cma.j.issn.1000-6680.2015.07.008. 韦智, 苏明华, 江建宁, 等. 广西地区丙型肝炎病毒基因6型的流行特征及治疗分析[J]. 中华传染病杂志, 2015, 33(7): 409-414. DOI: 10.3760/cma.j.issn.1000-6680.2015.07.008.
[19]	BENÍTEZ-GUTIÉRREZ L, BARREIRO P, LABARGA P, et al. Prevention and management of treatment failure to new oral hepatitis C drugs[J]. Expert Opin Pharmacother, 2016, 17(9): 1215-1223. DOI: 10.1080/14656566.2016.1182156.
[20]	HLAING N, MITRANI RA, AUNG ST, et al. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience[J]. J Viral Hepat, 2017, 24(11): 927-935. DOI: 10.1111/jvh.12721.
[21]	MOTAWI T, SHAKER OG, HUSSEIN RM, et al. Polymorphisms of α1- antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection[J]. Balkan J Med Genet, 2016, 19(2): 35-44. DOI: 10.1515/bjmg-2016-0034.
[22]	YANG G, SU MH, JIANG JN, et al. Resistance-associated variants in the non-structural protein 5B region in patients with hepatitis C virus genotype 1b infection in Guangxi, China[J]. J Clin Hepatol, 2019, 35(5): 992-995. DOI: 10.3969/j.issn.1001-5256.2019.05.012. 阳光, 苏明华, 江建宁, 等. 广西地区HCV 1b型感染者NS5B区基因耐药多态性分析[J]. 临床肝胆病杂志, 2019, 35(5): 992-995. DOI: 10.3969/j.issn.1001-5256.2019.05.012.
[23]	ASSELAH T, LEE SS, YAO BB, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5, 6): An open-label, multicentre, phase 3b trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(1): 45-51. DOI: 10.1016/S2468-1253(18)30341-8.
[24]	KU KS, CHODAVARAPU RK, MARTIN R, et al. Sequencing analysis of NS3/4A, NS5A, and NS5B genes from patients infected with hepatitis C virus genotypes 5 and 6[J]. J Clin Microbiol, 2016, 54(7): 1835-1841. DOI: 10.1128/JCM.00238-16.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (464) PDF downloads(44)

Epidemiological features and antiviral response of genotype 6 chronic hepatitis C

DOI: 10.3969/j.issn.1001-5256.2022.04.011

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content